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Brugada syndrome (BrS) is an inherited cardiac disorder that is associated with an electrocardiogram
pattern of ST segment elevation on right precordial leads and a high incidence of sudden death. Diagnosis
requires documentation of a coved-type ST segment that occurs spontaneously or in the presence of a
class IA or IC antiarrhythmic agent. A wide variety of other drugs, including antianginals, antidepressants,
antipsychotics, and antihistamines, have been reported to unmask or induce the electrocardiographic
and arrhythmic manifestations of BrS. This review focuses on drug-induced BrS phenotypes, prevalence,
and underlying mechanisms.
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Brugada syndrome (BrS) is an inherited cardiac arrhythmia
syndrome that is associated with ST segment elevation on right
precordial leads and a relatively high incidence of sudden cardiact Rhythm Society. Published by Els
ital, 1-5-8 Hatanodai Shina-
oura).death. BrS is characterized by an electrocardiogram (ECG) pattern
manifesting as prominent J waves, giving the appearance of an ST
segment elevation in the right precordial leads on an ECG.
Diagnostic criteria require the presence of a coved-type ST
segment elevation with a J point elevation ≥2 mV [1].
The BrS ECG is often widely dynamic, with ST segment eleva-
tions that ﬂuctuate from hour to hour, day to day, and month to
month. Diurnal variation shows that events occur more frequently
at night during periods of high vagal tone [2]. In some patients, theevier B.V. All rights reserved.
Table 1
Drugs that can cause the Brugada phenotype.
1. Antiarrhythmic drugs
Sodium channel blockers
Class IC drugs (pilsicainide, ﬂecainide, propafenone)
Class IA drugs (ajmaline, procainamide, disopyramide, cibenzoline)
Class III drugs (amiodarone)
Calcium channel blockers (verapamil)
Beta-blockers (propranolol intoxication)
2 Antianginal drugs
Calcium channel blockers (nifedipine, diltiazem)
Potassium channel opener (nicorandil)
3 Psychotropic drugs
Tricyclic antidepressants (amitriptyline, nortriptyline, desipramine,
clomipramine)
Phenothiazine
Selective serotonin reuptake inhibitors (ﬂuoxetine)
Lithium
Anticonvulsants (oxcarbazepine, clonazepam)
Antipsychotics (triﬂuoperazine, loxapine)
4 Other drugs
Anesthetics (bupivacaine, propofol)
Histaminic H1 receptor antagonists
Acetylcholine, edrophonium
Cocaine
Alcohol
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useful for diagnosing BrS.
The concealed BrS phenotype can be unmasked using class IA and
IC antiarrhythmic drugs, which possess potent use-dependent
sodium channel blocking activity [3]. These drugs induce or exagge-
rate the appearance of a coved-type ST with J point elevation (type
1 BrS ECG) and can convert type 2 to type 3 ST segment elevations to
type 1 (coved-type) elevations. Pilsicainide (Japan), procainamide
(USA), ajmaline (Europe), and ﬂecainide (Europe) have all demon-
strated good efﬁcacy in unmasking BrS and have become valuable
tools for the diagnosis of BrS [4,5].
In addition to antiarrhythmic drugs, a wide variety of other drugs
have been reported to unmask or induce the ECG and arrhythmic
manifestations of BrS, including antianginals, antidepressants, anti-
psychotics, and antihistamines (Table 1). Postema et al. recently
created a website that tracks drugs that are capable of causing
adverse events in patients with BrS (w w w.brugadadrugs.org) [6].
BrS has been associated with mutations in 12 different genes.
More than 300mutations in SCN5A (Nav1.5, BrS1) have been reported
in 11–28% of BrS probands [7–9]. Mutations in CACNA1C (Cav1.2,
BrS3), CACNB2b (Cavβ2b, BrS4), and CACNA2D1 (Cavα2δ, BrS9) are
found in approximately 13% of probands [10,11]. Mutations in the
glycerol-3-phosphate dehydrogenase 1-like enzyme gene (GPD1L,
BrS2), the β1-subunit of Na channel (SCN1B, BrS5) KCNE3 (MiRP2,
BrS6), the β3-subunit of Na channel (SCN3B, BrS7) KCNJ8 (BrS8),
KCND3 (BrS10), MOG1 (BrS11), and SLMAP (BrS12) are more rare
[12–19]. Mutations in these genes lead to a loss of function in sodium
channel current (INa) and calcium channel current (ICa) as well as a
gain of function in the transient outward potassium current (Ito) or
adenosine triphosphate (ATP)-sensitive potassium current (IK-ATP).
Acquired forms of the BrS mimic some forms of the congenital
syndrome by reducing INa and ICa and by augmenting Ito and IK-ATP.2. Antiarrhythmic drugs
2.1. Sodium and calcium channel blockers (class IC and IA drugs)
Approximately one-fourth of cases of BrS are caused by a loss-
of-function mutation in SCN5A. Mutations in SCN5A (BrS1) has
been identiﬁed in 11–28% of BrS probands [9]. SCNB1 (BrS5),
SCN3B (BrS7), MOG1 (BrS11), and SLMAP (BrS12) are relatively
rare. These mutations are all associated with a loss of function of
sodium channel current that gives rise to a BrS phenotype. Like-
wise, agents that reduce INa give rise to BrS phenotypes, in most
cases by unmasking a congenital form of the syndrome.
Pharmacologic challenge by several sodium channel blockers is
an established tool for the diagnosis of BrS. Sodium channel
blockers such as pilsicainide, ajmaline, and ﬂecainide are capable
of inducing ST segment elevations and unmasking a concealed BrS
phenotype.
Pilsicainide is a class I sodium channel blocker antiarrhythmic
drug that is used principally in Japan. Its primary indication is for
the treatment of atrial tachyarrhythmias, including atrial ﬁbrilla-
tion. Fig. 1 shows the results of a pilsicainide challenge in a case of
BrS. Pilsicainide was given intravenously at a dose of 1.0 mg/kg
over 10 min. After administration, the J point and ST segment are
elevated and display a coved-type or type I ST segment elevation.
Sodium channel blockers can unmask a type I ST segment eleva-
tion or convert a type 2 (saddleback) ST segment elevation to a
type 1 BrS pattern, as in this case.
Late potentials (LP) in signal-averaged electrocardiograms
(SAECG) have been reported to correlate with the unmasking of
a coved-type (type 1) ST segment elevation by pilsicainide [20].
Fig. 2 shows the SAECG before and after pilsicainide administra-
tion in a BrS case. The SAECG was normal in controls but displayedLP after pilsicainide administration. LP are traditionally thought to
be due to delayed activation of the myocardium, but in the case of
BrS has been suggested to be the result of accentuation of
abnormal repolarization (delayed second upstroke of the epicar-
dial action potential [AP] and concealed phase 2 reentry) in the
region of the right ventricular outﬂow tract (RVOT) [21].
Pilsicainide, as well as other sodium channel blockers, including
propafenone and ﬂecainide, can cause the appearance of a BrS ECG
when it is routinely used for the treatment of atrial ﬁbrillation.
Wolpert et al. compared the effects of intravenous ﬂecainide and
ajmaline with respect to their ability to induce or accentuate the
typical ECG pattern of BrS [22]. A coved-type ST segment elevation in
the right precordial leads was induced or enhanced in 22 of 22
patients following ajmaline administration but in only 15 patients in
response to ﬂecainide. The authors presented evidence in support of
the hypothesis that greater inhibition of Ito by ﬂecainide renders it
less effective. Blockage of Ito counters the effect of the drug and
causes an outward shift of the balance of current activity during the
early phases of the AP.
To our knowledge, there are no data relative to pilsicainide
blockage of Ito. Pilsicainide may be the most powerful agent for
unmasking BrS, although a direct comparison between ajmaline
[23] and pilsicainide [24] is not available.2.2. Calcium channel blockers (verapamil)
Mutations in CACNAC1C (BrS3), CACNB2b (BrS4), and CACNA2D1
(BrS9) have been associated with BrS in approximately 13%
probands [10,11]. Experimental models have shown that verapa-
mil accentuates the epicardial AP notch and produces the BrS
phenotype [25]. Fish et al. reported that the use of a combination
sodium and calcium channel block may be more effective than the
use of a sodium channel blocker alone in causing the BrS
phenotype [26]. In clinical cases, verapamil was reported to cause
ST segment elevation and permit the induction of programmed
electrical stimulation-induced VT/VF in a case of BrS [27].
V1
V2
V3
V4
V5
V6
Fig. 1. Electrocardiographic recordings in a pilsicainide challenge test in a patient with Brugada syndrome. (A) At baseline, a saddleback-type ST segment (type 2) is present
in the right precordial leads. (B) Intravenous administration of pilsicainide (50 mg) converts type 2 ST segment elevation to a coved-type ST segment (type 1), thus
unmasking the Brugada syndrome phenotype.
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Because β-adrenergic agonists such as isoproterenol (ISO) exert
ameliorative effects on BrS, β-adrenergic blockers may exert a pro-
arrhythmic effect. Propranolol, a non-selective β1-adrenergic
agent, was reported to cause the BrS pattern on ECG during
intoxication [28]. It is noteworthy that high concentrations of
propranolol can inhibit INa, leading to the outward shift of the
current active during phases 1 and 2 [28].3. Antianginal drugs
3.1. ATP-sensitive potassium channel opener
ATP-sensitive potassium channels are found in the heart,
pancreas, smooth muscles, skeletal muscles, brain, and kidneys.
KATP channels consist of four pore-forming Kir6.x subunits and
four regulatory ATP-sensing sulfonylurea receptor (SURx) subu-
nits. Kir6.2/Kir6.1 is encoded by KCNJ11/KCNJ8, respectively, while
SUR2A/SUR1 is encoded by ABCC9/ABCC8, respectively. IK-ATPagonists such as nicorandil exert their antianginal actions by
causing vasodilation and improving coronary blood ﬂow.
Mutations in KCNJ8 (BrS8), the gene encoding Kir6.1, and
ABCC9, the gene encoding the ATP-sensing subunit SUR2A
(BrS12), have been reported to cause a gain of function of IK-ATP,
and thus contribute to the development of a BrS phenotype
[15,29]. The KATP channel is activated by a reduction of intracel-
lular ATP. This appears to be more readily achieved in the
epicardium than in the endocardium [30]. Miyoshi et al. showed
a greater induction of IK-ATP in the epicardium in response to
ischemia and suggested that it was due to either a lower threshold
for activation or a denser distribution of KATP channels or other Kþ
channels at the epi layer [31]. Pinacidil, an IK-ATP channel opener,
has been shown to induce the BrS phenotype in experimental
models of BrS [32,33].
There are only few case reports of the BrS phenotype being
induced by antianginal drugs alone. However, a combination of
nifedipine and isosorbide dinitrate (ISDN) has been reported to
induce a BrS phenotype [34]. Cases of coexistent vasospastic
angina and BrS [35] have also been reported. Acetylcholine-
induced coronary vasospasm has likewise been reported to cause
Fig. 2. Signal-averaged electrocardiogram (SAECG) before and after the intravenous administration of pilsicainide in a BrS case. (A) In controls, SAECG was normal with no
late potential manifests. (B) Intravenous administration of pilsicainide (50 mg) induced the appearance of late potential (ﬁltered-QRS was prolonged [138 ms vs. 160 ms] and
root-mean square voltage was reduced [12.8 mV vs. 7.8 ms]).
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vasospasm and BrS is rare.4. Psychotropic drugs
4.1. Tricyclic antidepressants (amitriptyline, nortriptyline,
desipramine, and clomipramine)
Psychotropic drugs are well recognized to induce cardiac
arrhythmias and can cause an ST segment elevation consistent
with BrS [38]. Tricyclic antidepressants have been reported to
induce the BrS pattern on ECG over a wide range of antidepressant
dosages [39]. Amitriptyline, a tricyclic antidepressant, has recently
been reported to induce the BrS phenotype in clinics [40–43] as
well as in an experimental model [44]. Amitriptyline was shown to
cause an outward shift in the balance of current activity during the
early phases of the epicardial AP by reducing the peak sodium
channel current.
Figs. 3 and 4 show that the effect of amitriptyline in the
reduction of INa and induction of the BrS phenotype in a right
ventricular wedge with NS5806 (Ito agonist) caused loss of the AP
dome in Epi2 and led to phase 2 reentry and polymorphic
ventricular tachycardia (VT). Amitriptyline alone did not induce
any arrhythmias, suggesting that amitriptyline-induced inhibitionof INa unmasks the Brugada ECG phenotype and facilitates the
development of an arrhythmogenic substrate only in the setting of
a genetic predisposition by creating repolarization heterogeneities
that give rise to phase 2 reentry and VT. Amitriptyline can also
block Ito [45], explaining why it fails to induce the BrS phenotype
even at high concentrations (1 mM). The effect of tricyclic anti-
depressants for blocking INa has been documented in several
studies [46,47]. Amitriptyline has also been reported to prolong
the QT interval because of its ability to block IKr [48].5. Lithium
Lithium is widely used to treat depression and bipolar disorder.
The lithium-induced BrS phenotype is not common, but it can be
observed even with use of therapeutic dosages [49]. Lithium also
causes other conduction dysfunctions such as sinus node dysfunc-
tion, conduction block, and ventricular arrhythmias. Lithium has
also been shown to block INa in a dose-dependent manner [50].6. Selective serotonin reuptake inhibitors
Data regarding the selective serotonin reuptake inhibitor (SSRI)-
induced BrS phenotype are scarce. Paroxetine and ﬂuvoxamine have
Fig. 3. Amitriptyline-induced Brugada phenotype in a coronary-perfused right ventricular wedge preparation. Action potentials (APs) recorded from an endocardial and two
epicardial sites, together with a pseudo-electrocardiogram (ECG). The transient outward potassium current agonist leads to the accentuation of the epicardial AP notch and J
wave in the ECG. Amitriptyline in the presence of NS5806 induces the Brugada ECG phenotype and polymorphic ventricular tachycardia. NS5806, transient outward
potassium channel current agonist. (Modiﬁed from Minoura and Antzelevitch [44] with permission.)
Fig. 4. Amitriptyline blocks the sodium channel current in TSA201 cells transfected with SCN5A and SCN1B. (A) Amitriptyline blocks peak INa at þ20 mV (Po0.01).
(B) Steady-state inactivation curve. Amitriptyline shifts the half-inactivation potential by −20 mV (Po0.01). TSA201 cells, a transformed human kidney cell line; NS5806, a
transient outward potassium channel current agonist. (Modiﬁed from Minoura and Antzelevitch [44] with permission.)
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[51,52].7. Anticonvulsant and antipsychotics
Phenytoin is an antiepileptic agent. There are case reports of
BrS caused by supratherapeutic phenytoin levels in a patient with
a seizure disorder [53]. There are several reports of ECG signs ofBrS in cases of hyperkalemia in conjunction with psychotropic
drug overdoses, notably phenothiazines [54].8. Anesthesia
Anesthetics such as propofol and bupivacaine are commonly
used in clinical settings. Bupivacaine was reported to induce the
BrS phenotype in silent carriers of an SCN5A mutation [55].
Fig. 5. Effect of isoproterenol and quinidine in the suppression of Brugada syndrome induced by amitriptyline in a coronary-perfused right ventricular wedge preparation.
Action potentials (APs) recorded from one endocardial and two epicardial sites together with a pseudo-electrocardiogram (ECG). (A) and (B) show traces recorded in controls,
after NS5806 (8 mM) administration, and after further addition of amitriptyline (0.2 mM). Amitriptyline accentuated the AP notch and the J wave, leading to phase 2 reentry
and polymorphic ventricular tachycardia (pVT). The addition of isoproterenol or quinidine restored the AP dome and suppressed the pVT. NS5806, transient outward
potassium channel current agonist. (Modiﬁed from Minoura and Antzelevitch [44] with permission.)
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phenotype that normalized following drug withdrawal.
Propofol has been reported to cause sudden cardiac death in
one non-genetic and 6 unclear cases [56]. Propofol has been
shown to inhibit neuronal sodium channels [57], but there are
no data relative to cardiac sodium channels. It is unclear whether a
genetic predisposition is present in those who display a BrS
phenotype after propofol administration.9. Other drugs
Overdose of diphenhydramine (an H1 histamine receptor
antagonist) is reported to induce a BrS phenotype [58,59]. Anti-
histamines are known to cause QT prolongation secondary to IKr
inhibition. Cocaine is known to block the sodium channels and
thus to unmask a BrS phenotype [60]. Alcohol intoxication is also
reported to induce a BrS phenotype [61]. Interestingly, a full
stomach after a large meal is known to induce a BrS phenotype
[62]. This response it believed to be due to increased parasympa-
thetic tone. Any agent capable of producing an outward shift in the
balance of current during the early phases of the epicardial AP is
expected to be capable of creating or unmasking a BrS phenotype.10. Mechanism underlying drug-induced BrS
Our working hypothesis regarding the mechanisms underlying
induction of the drug-induced BrS phenotype is that these drugs
produce an outward shift in the balance of current activity during
the early phases of the epicardial AP, similar to the mechanism
underlying the development of congenital BrS. Th is can be
accomplished either by inhibition or reduction of depolarizing
inward currents such as INa or ICa or augmentation of a repolarizing
outward current such as Ito [25].
The outward shift of net current leads to the accentuation of
the epicardial AP notch, which in turn causes loss of the AP dome
in the right ventricular (RV) epicardium. The loss of the dome
results in both epicardial and transmural dispersion of repolariza-
tion, which gives rise to an ST segment elevation and creates a
vulnerable period within the RV wall. The epicardial dispersion of
repolarization can result in phase 2 reentry, thus creating a closelycoupled premature beat capable of capturing the vulnerable
window and precipitating polymorphic VT [1,63,64].
BrS is a right ventricular disease because Ito is most prominent
in the right ventricle. Ito is also much more prominent in the
epicardium than in the endocardium, which is responsible for the
prominent AP notch in the epicardium but not the endocardium.
This heterogeneous distribution of Ito and the AP notch is respon-
sible for inscription of the J wave [65].
Recent studies have proposed that delayed conduction in the
RVOT is responsible for some cases of BrS [66,67]. A debate of the
repolarization vs. depolarization hypothesis for BrS is the subject
of a point counterpoint published in 2010 [68].11. Treatment for the drug-induced BrS
Drug withdrawal is an effective treatment strategy in most
cases of drug-induced BrS. In those cases in which additional
measures are necessary, therapy is aimed at rebalancing the
current activity during the early phases of the epicardial AP, either
by increasing ICa or reducing Ito. The increase in ICa can be achieved
with the administration of ISO, which is especially effective in
suppressing drug-induced VF storms in BrS cases in the emer-
gency room. ISO can also effectively suppress VF in drug-induced
BrS. ICa augmentation can also be achieved with the phosphodies-
terase III inhibitor, cilostazol. The reduction of Ito is best achieved
using quinidine. Fig. 5 illustrates the ability of quinidine and ISO to
suppress the BrS phenotype in experimental models of BrS.
Quinidine also blocks INa, IKr, and IKs at therapeutic plasma levels,
but its usefulness for the treatment of BrS is well established both
in experimental studies and clinical cases [69].Conﬂicts of interest
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